Abstracts tagged "autoantibodies"

Abstract Number: 387 • 2014 ACR/ARHP Annual Meeting
Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA
Caroline Grönwall¹, Lelise Getu², Jeffrey D. Greenberg³, Robert M. Clancy⁴ and Gregg J. Silverman¹, ¹Medicine, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Monitoring disease activity in patients with autoimmune rheumatic disease is an essential part of clinical care. Highly reactive malondialdehyde (MDA) arise from reactive oxygen…
Abstract Number: 2016 • 2014 ACR/ARHP Annual Meeting
Occupation and Risk of Developing Rheumatoid Arthritis
Anna Ilar¹, Pernilla Wiebert¹, Lars Klareskog², Lars Alfredsson¹ and Camilla Bengtsson¹, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose The role of environmental factors in the etiology of rheumatoid arthritis (RA) is still fairly unknown. Finding occupations associated with the risk of disease…
Abstract Number: 1255 • 2014 ACR/ARHP Annual Meeting
Pathogenic Role of Tyrosyl–Transfer RNA Synthetase in Anti-Synthetase Syndrome
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Manabu Kawamoto¹, Ken Iwaki², Miki Miyanokoshi², Keisuke Wakasugi², Koji Tahara³, Kaori Ito³, Hiroaki Hattori³, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan, ³Advanced Medical Technology and Development, BML, Saitama, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose : Autoantibodies directed against the aminoacyl transfer RNA (tRNA) synthetases are associated with myositis, arthritis, Raynaud’s phenomenon, mechanic’s hands, fever, and interstitial lung disease,…
Abstract Number: 359 • 2014 ACR/ARHP Annual Meeting
14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
Anthony Marotta¹, Samina Turk², Mairead Murphy³, Walter P. Maksymowych⁴ and Dirkjan van Schaardenburg⁵, ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Reade, Amsterdam, Netherlands, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, there are auto-antibodies (AAb) to…
Abstract Number: 1939 • 2014 ACR/ARHP Annual Meeting
Development of Cell–Based Enzyme–Linked Immunosorbent Assay for the Quantification of Anti–M–type phospholipase–a–receptor Antibodies and Its Clinical Usefulness in Patients with Membranous Nephropathy
Yasuhiro Katsumata¹, Yuko Okamoto¹, Takahito Moriyama², Manabu Kawamoto¹, Hirotaka Kaneko¹, Yasushi Kawaguchi¹, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹, Keiko Uchida², Kosaku Nitta² and Hisashi Yamanaka³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose : Better risk prediction is needed to identify patients who will benefit from immunosuppressive therapy with idiopathic membranous nephropathy (MN) due to the variable…
Abstract Number: 1169 • 2014 ACR/ARHP Annual Meeting
Hippocampal Atrophy Is Associated with Anti-NR2 Antibodies in Patients with Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Maria B Lauvsnes¹, Mona K Beyer², Jan T Kvaløy^3,4, Ole J Greve⁵, Simone Appenzeller⁶, Erna Harboe⁷, Anne B Tjensvoll⁸, Lasse G Gøransson⁷ and Roald Omdal⁹, ¹Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ³Research Department, Stavanger University Hospital, Stavanger, Norway, ⁴Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway, ⁵Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁶Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil, ⁷Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ⁹Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Antibodies against the NR2 subtype of the NMDA-receptor (anti-NR2 antibodies) are detected in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (SS).…
Abstract Number: 1907 • 2014 ACR/ARHP Annual Meeting
Clinical Evaluation of Anti-Aminoacyl tRNA Synthase Antibodies in Rheumatoid Arthritis Patients
Masakazu Matsushita¹, Ken Yamaji¹, Naoto Tamura² and Yoshinari Takasaki³, ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Anti-Jo-1 is an autoantibody that is specifically detected in the blood sera of patients with polymyositis/dermatomyositis (PM/DM). The corresponding antigen is known to be…
Abstract Number: 1037 • 2014 ACR/ARHP Annual Meeting
Anti-MDA5 Antibody Associated Myositis Compared to DM Patient: A Distinct Muscular Pattern Associated with a shared IFN Signature
Yves Allenbach^1,2,3, Gaelle Leroux⁴, Aude Rigolet², Baptiste Hervier⁵, Nicolas Limal⁶, Peter Hufnagl⁷, Norman Zerbe⁸, Thierry Maisonobe⁹, Alain Meyer¹⁰, Yurdagul Uzunhan¹¹, Kuberaka Mariampillai¹², Romain Gherardi¹³, Serge Herson¹², Olivier Benveniste^2,3 and Werner Stenzel¹⁴, ¹Neuropathology, Charite Hospital, Berlin, Germany, ²Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ³UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁵Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ⁷Pathology departmen, Charite Hospital, Berlin, Germany, ⁸Department of Pathology, Charite Hospital, Berlin, Germany, ⁹Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Pneumology, APHP Avicenne Hospital, Bobigny, France, ¹²Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ¹³Pathology, APHP Henri Mondor Hospital, Creteil, France, ¹⁴Department of Neuropathology, Charite Hospital, Berlin, Germany
Background/Purpose Anti-MDA5 auto-antibodies are thought to be specifically associated with dermatomyositis (DM). Nevertheless anti-MDA5 auto-antibody positive patients (MDA5+ DM) predominantly suffer from extra-muscular involvement with severe…
Abstract Number: 3000 • 2014 ACR/ARHP Annual Meeting
Comparison of Systemic Sclerosis Subsets As Predictors of Mortality and Morbidity
Hebah Alhajeri¹, Marie Hudson^2,3, Canadian Scleroderma Research Group CSRG⁴ and Murray Baron⁵, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Division of Rheumatology, McGill University, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Identifying systemic sclerosis (SSc) subsets that predict mortality and morbidity could provide useful prognostic information. We undertook this study to compare the predictive ability…
Abstract Number: 1730 • 2014 ACR/ARHP Annual Meeting
Identification of Novel Scleroderma –associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation
Hans-Dieter Zucht¹, Petra Budde¹, Peter Schulz-Knappe¹, Nicolas Hunzelmann², Karsten Conrad³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Dermatology, University of Cologne, Cologne, Germany, ³Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁴Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany
Background/Purpose: Scleroderma (systemic sclerosis or SSc) has a highly variable clinical presentation and course resulting in difficulties for disease management. When SSc is suspected, autoantibodies…
Abstract Number: 984 • 2014 ACR/ARHP Annual Meeting
Apolipoprotein B Is a Target of T and B Cell Responses in a Subgroup of Patients with Lyme Disease
Jameson T. Crowley¹, Elise E. Drouin², Qi Wang³, Gail McHugh⁴, Catherine E. Costello³ and Allen C. Steere⁵, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, ⁴Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁵Medicine, Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose Borrelia burgdorferi-induced autoimmunity in affected joints has been hypothesized to be a contributing factor to antibiotic-refractory Lyme arthritis (ARLA). Our prior study, which combined…
Abstract Number: 2985 • 2014 ACR/ARHP Annual Meeting
Autoantibodies to 14-3-3η Are Novel Biomarkers Associated with Inflammation and Radiographic Progression in Ankylosing Spondylitis
Walter P. Maksymowych¹, Stephanie Wichuk¹, RG Lambert², Mairead Murphy³ and Anthony Marotta⁴, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Radiology, University of Alberta, Edmonton, AB, Canada, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a ubiquitous intracellular chaperone protein that is expressed extracellularly in rheumatoid arthritis and mediates inflammatory cascades that result in expression of inflammatory…
Abstract Number: 1708 • 2014 ACR/ARHP Annual Meeting
The Pathogenic Role of Immune Complexes Containing Scleroderma-Specific Autoantibodies in the Inductor Phase of the Disease
Cecilia B. Chighizola¹, Elena Raschi², Laura Cesana², Silvana Zeni³, Maria Orietta Borghi⁴ and Pier Luigi Meroni^5,6, ¹Rheumatology, Istituto Auxologico Italiano, University of Milan, Cusano Milanino, Italy, ²Istituto Auxologico Italiano, Milan, Italy, ³Division of Rheumatology, Istituto G. Pini, Milano, Italy, ⁴Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁵Department of Clinical Sciences and Community Health, Division of Rheumatology, Istituto G. Pini, Milan, Italy, ⁶Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune condition characterized by excessive tissue fibrosis, microvascular alterations and immune dysfunction with the production of peculiar autoantibodies.…
Abstract Number: 982 • 2014 ACR/ARHP Annual Meeting
Identification of Potential SERUM Autoantibody Biomarkers in Rheumatic Diseases Using a New Generation of Protein Arrays
Lucia Lourido¹, Juan Fernandez-Tajes¹, Valentina Calamia¹, Carolina Fernandez-Costa^1,2, Beatriz Rocha¹, Patricia Fernandez-Puente¹, Jesus Mateos¹, Carlos Fernandez-Lopez¹, Natividad Oreiro-Villar¹, Manuel Fuentes³, Francisco J. Blanco Garcia¹ and Cristina Ruiz-Romero¹, ¹Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ²Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A coruña, Spain, ³Centro de Investigación del Cáncer/IBMCC (USAL/CIC), IBSAL, Departamento de Medicina, Unidad de Proteomica Servicio general de Citometría, Universidad de Salamanca, Salamanca, SPAIN., Salamanca, Spain
Background/Purpose Osteoarthritis (OA) is characterized by the loss of structural components from the extracelullar matrix (ECM) of articular cartilage. The progressive release of proteins from…
Abstract Number: 2991 • 2014 ACR/ARHP Annual Meeting
Anti-Ribosomal P Antibody Is a Key Autoantibody Associated with Complications of NP-SLE with High-Levels of CSF IL-8
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Complications of neuropsychiatric systemic lupus erythematosus (NP-SLE) are associated with the morbidity and mortality of patients with SLE. Although the detailed pathophysiology of NP-SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.